8-KShareholder MattersCorporate ChangesOther Events+1

PNC FINANCIAL SERVICES GROUP, INC. 8-K Report, Rights Modification (May 7, 2013)

Filed May 7, 2013For Securities:PNC

Summary

PNC Financial Services Group, Inc. (PNC) filed an 8-K on May 7, 2013, to report the establishment and subsequent closing of a public offering for its new Series R Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock. This new series of preferred stock is structured to be senior to common stock and rank equally with other existing preferred stock, providing a specific dividend structure and liquidation preference. The offering involved 500,000 depositary shares, each representing a 1/100th interest in a share of the Series R Preferred Stock. The stock features a fixed dividend rate of 4.850% annually for the first ten years (until June 1, 2023), transitioning to a floating rate of three-month LIBOR plus 3.04% thereafter. This issuance is a strategic move by PNC to enhance its capital structure, likely in response to regulatory requirements or to fund growth initiatives.

Key Highlights

  • 1PNC established a new series of preferred stock: Series R Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock.
  • 2The company filed a Statement with Respect to Shares on May 3, 2013, outlining the terms of the Series R Preferred Stock.
  • 3PNC successfully closed a public offering of 500,000 depositary shares, each representing a 1/100th interest in the Series R Preferred Stock, on May 7, 2013.
  • 4The Series R Preferred Stock has a liquidation preference of $100,000 per share, with dividends being non-cumulative.
  • 5Dividends are fixed at 4.850% annually until June 1, 2023, then transition to a floating rate (3-month LIBOR + 3.04%).
  • 6The Series R Preferred Stock ranks senior to common stock and pari passu with other specified series of preferred stock.
  • 7The Series R Preferred Stock has no maturity date and is redeemable under specific conditions, including after June 1, 2023, or following a regulatory capital treatment event.

Frequently Asked Questions